Detalhe da pesquisa
1.
Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): final analysis of a phase III, randomized, double-blind, placebo-controlled study.
Breast Cancer Res Treat
; 197(3): 503-513, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36463547
2.
ASTEFANIA: adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancer.
Future Oncol
; 18(32): 3563-3572, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36382554
3.
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.
Lancet Oncol
; 21(4): 519-530, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32171426
4.
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
N Engl J Med
; 377(2): 122-131, 2017 Jul 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-28581356
5.
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.
N Engl J Med
; 366(2): 109-19, 2012 Jan 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-22149875
6.
Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA.
Oncologist
; 19(7): 693-701, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24869931
7.
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.
Lancet Oncol
; 14(6): 461-71, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23602601
8.
Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study.
Oncologist
; 18(3): 257-64, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23475636
9.
Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA).
Breast Cancer Res Treat
; 142(1): 89-99, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-24129974
10.
Real-World First-Line Use of Pertuzumab With Different Taxanes for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Comparative Effectiveness Study Using US Electronic Health Records.
JCO Oncol Pract
; 19(7): 435-445, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37167571
11.
Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled Analysis.
Cancers (Basel)
; 14(20)2022 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36291835
12.
Pharmacokinetic and exploratory exposure-response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study.
Cancer Chemother Pharmacol
; 83(6): 1147-1158, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30976844
13.
Exposure-response analysis of pertuzumab in HER2-positive metastatic breast cancer: absence of effect on QTc prolongation and other ECG parameters.
Cancer Chemother Pharmacol
; 72(5): 1133-41, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-23999693
14.
In vitro motility analysis of thin filaments from failing and non-failing human heart: troponin from failing human hearts induces slower filament sliding and higher Ca(2+) sensitivity.
J Mol Cell Cardiol
; 34(4): 469-82, 2002 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-11991735
15.
Two mutations in troponin I that cause hypertrophic cardiomyopathy have contrasting effects on cardiac muscle contractility.
Biochem J
; 362(Pt 2): 443-51, 2002 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-11853553
16.
Alterations in thin filament regulation induced by a human cardiac troponin T mutant that causes dilated cardiomyopathy are distinct from those induced by troponin T mutants that cause hypertrophic cardiomyopathy.
J Biol Chem
; 277(43): 40710-6, 2002 Oct 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-12186860